Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gabapentin
Drug ID BADD_D00981
Description Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993.[L8717] It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin].
Indications and Usage In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]
Marketing Status approved; investigational
ATC Code N02BF01
DrugBank ID DB00996
KEGG ID D00332
MeSH ID D000077206
PubChem ID 3446
TTD Drug ID D0J0ZS
NDC Product Code 72789-055; 72888-132; 76420-235; 80425-0031; 80425-0097; 80425-0182; 82009-071; 52133-0025; 62331-031; 64220-211; 69617-002; 71574-121; 71901-609; 16714-332; 25000-103; 42385-974; 43602-466; 49483-607; 51407-047; 0228-2636; 52427-815; 53002-3423; 55289-959; 55700-584; 60687-591; 61919-640; 62756-202; 63187-006; 63187-010; 63187-810; 63629-7666; 63629-8490; 63739-560; 63739-591; 67877-429; 68001-412; 68071-5193; 68382-205; 68788-7822; 68788-7839; 68788-8176; 70010-926; 70518-0810; 70518-1760; 71093-120; 71205-317; 71205-485; 71205-619; 71205-638; 71335-0351; 71335-1007; 71335-1132; 71335-1200; 71335-1269; 71335-1496; 71610-044; 71610-621; 72789-127; 76282-706; 80425-0286; 83301-0002; 45963-556; 57884-0010; 65977-0054; 0071-0803; 16714-504; 42385-972; 43602-470; 50383-311; 50383-351; 51224-219; 51407-048; 51407-049; 52427-850; 53002-1538; 55700-780; 55700-950; 60687-518; 60760-088; 60760-814; 61919-387; 62756-139; 63187-372; 63187-392; 63629-8485; 63629-8487; 63739-236; 65162-102; 65862-524; 67877-428; 68071-3445; 69367-344; 70010-927; 70518-3330; 71093-122; 71205-373; 71205-533; 71335-0073; 71335-1287; 71335-2004; 71610-057; 71610-060; 71610-088; 71610-166; 71610-410; 71610-426; 0615-8132; 0615-8233; 0615-8340; 76420-234; 80425-0128; 83301-0001; 42765-018; 65862-523; 16714-663; 17856-0698; 42806-509; 42806-510; 43353-075; 43353-081; 43353-864; 43602-467; 43602-469; 45865-122; 49483-606; 50090-0949; 50090-3915; 50228-178; 50268-325; 51224-019; 55154-8193; 55154-8195; 59088-725; 59762-5050; 60687-602; 62756-137; 62756-138; 63187-909; 65862-200; 68071-2308; 68071-2600; 68071-2883; 68071-2907; 68462-126; 68788-7838; 68788-8475; 69097-811; 69097-814; 69367-131; 69367-133; 70518-1469; 70518-1544; 70518-2323; 70518-2912; 70518-2970; 70518-3755; 71205-932; 71335-1012; 71335-1655; 71610-198; 72189-394; 53746-101; 55154-3366; 59762-4135; 60760-605; 61919-350; 61919-417; 63187-057; 63629-8488; 63739-902; 64380-867; 68788-7024; 68788-7774; 68788-8468; 68788-8476; 70010-109; 70518-2911; 70518-3708; 71205-766; 71335-0254; 71335-0820; 71335-0993; 71335-1198; 71610-072; 72162-1813; 72189-419; 76420-047; 80425-0158; 82982-049; 82982-067; 17337-0415; 45963-557; 49452-3241; 65862-198; 66651-901; 0071-0401; 68554-0128; 82393-212; 16714-661; 31722-167; 45963-555; 49483-605; 50090-5961; 50228-180; 53002-4423; 55154-7993; 61919-982; 63187-148; 63187-983; 63739-903; 65841-705; 65841-706; 67296-1536; 68071-4978; 69367-134; 69367-135; 69367-346; 70010-118; 70518-3140; 70934-284; 70934-933; 71205-160; 71205-514; 71205-671; 71205-808; 71205-931; 71335-1018; 71335-1991; 71610-090; 71610-188; 72189-392; 0615-8342; 72888-104; 76282-405; 80425-0032; 80425-0033; 80425-0149; 0904-6665; 0228-2637; 65862-199; 68981-009; 71052-176; 0071-2012; 16571-868; 31722-149; 42385-973; 43602-471; 45865-405; 45865-498; 45865-549; 50090-3200; 50090-4445; 50090-4893; 50228-177; 50436-0223; 52427-804; 52427-890; 55700-949; 60760-066; 60760-740; 61919-660; 62207-927; 63187-056; 63187-149; 63187-248; 63629-3063; 63629-8489; 63629-8491; 63629-8492; 64380-868; 68071-2206; 68788-7848; 68788-8199; 69097-813; 69097-815; 69844-055; 69844-056; 70010-228; 70518-2493; 70518-3103; 70518-3329; 70934-950; 70934-953; 71093-111; 71093-162; 71335-1199; 71335-1453; 71335-1997; 71335-2053; 71610-135; 71610-667; 72189-092; 72189-313; 72189-384; 72888-131; 76282-323; 80425-0035; 80425-0082; 80425-0150; 82009-072
UNII 6CW7F3G59X
Synonyms Gabapentin | 1-(Aminomethyl)cyclohexaneacetic Acid | Neurontin | Gabapentin Hexal | Convalis | Gabapentin-Ratiopharm | Gabapentin Ratiopharm | Novo-Gabapentin | Novo Gabapentin | NovoGabapentin | PMS-Gabapentin | Apo-Gabapentin | Apo Gabapentin | ApoGabapentin | Gabapentin Stada
Chemical Information
Molecular Formula C9H17NO2
CAS Registry Number 60142-96-3
SMILES C1CCC(CC1)(CC(=O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Serotonin syndrome17.05.02.004; 12.03.01.041; 15.05.04.0160.000099%Not Available
Sexual dysfunction21.03.02.003; 19.08.05.0020.000166%Not Available
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin atrophy23.01.05.001--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin fissures23.03.03.0080.000031%Not Available
Skin hypertrophy23.01.04.002--Not Available
Skin necrosis23.03.03.011--Not Available
Skin odour abnormal23.03.03.0120.000016%
Skin ulcer24.04.03.007; 23.07.03.0030.000101%
Sleep apnoea syndrome19.02.05.002; 22.02.01.013; 17.15.05.0010.000056%
Sleep disorder19.02.04.0010.000482%Not Available
Sleep talking17.15.02.003; 19.02.03.0050.000023%Not Available
Sluggishness08.01.01.0040.000082%Not Available
Snoring22.12.03.025--Not Available
Somnambulism17.15.02.004; 19.02.03.0060.000056%Not Available
Somnolence19.02.05.003; 17.02.04.0060.006187%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000421%Not Available
Spinal osteoarthritis15.01.04.0030.000039%Not Available
Status epilepticus17.12.03.0050.000068%Not Available
Stereotypy19.11.03.006; 17.01.02.0160.000021%Not Available
Stevens-Johnson syndrome23.03.01.007; 10.01.01.045; 12.03.01.014; 11.07.01.005--
Stillbirth18.01.02.002; 08.04.01.0060.000037%Not Available
Stomatitis07.05.06.005--
Strabismus17.17.01.009; 06.05.02.0040.000031%Not Available
Stress19.06.02.004--Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene